217 related articles for article (PubMed ID: 24855903)
21. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
22. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
[TBL] [Abstract][Full Text] [Related]
23. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
Valentin R; Grabow S; Davids MS
Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
[TBL] [Abstract][Full Text] [Related]
24. Overview: A New Era of Cancer Genomics in Lymphoid Malignancies.
Iida S
Oncology; 2015; 89 Suppl 1():4-6. PubMed ID: 26551834
[TBL] [Abstract][Full Text] [Related]
25. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
Lipka DB; Kuck D; Kliem C; Gerhauser C
Expert Opin Ther Pat; 2013 Apr; 23(4):537-43. PubMed ID: 23448241
[TBL] [Abstract][Full Text] [Related]
26. Investigational drugs for the treatment of diffuse large B-cell lymphoma.
Patriarca A; Gaidano G
Expert Opin Investig Drugs; 2021 Jan; 30(1):25-38. PubMed ID: 33295827
[No Abstract] [Full Text] [Related]
27. The Syk kinase as a therapeutic target in leukemia and lymphoma.
Efremov DG; Laurenti L
Expert Opin Investig Drugs; 2011 May; 20(5):623-36. PubMed ID: 21438742
[TBL] [Abstract][Full Text] [Related]
28. Clinical advances in targeting epigenetics for cancer therapy.
Feng S; De Carvalho DD
FEBS J; 2022 Mar; 289(5):1214-1239. PubMed ID: 33545740
[TBL] [Abstract][Full Text] [Related]
29. Role of epigenetic in leukemia: From mechanism to therapy.
Liu XL; Liu HQ; Li J; Mao CY; He JT; Zhao X
Chem Biol Interact; 2020 Feb; 317():108963. PubMed ID: 31978391
[TBL] [Abstract][Full Text] [Related]
30. The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies.
Pantazis P
Leuk Res; 1995 Nov; 19(11):775-88. PubMed ID: 8551794
[TBL] [Abstract][Full Text] [Related]
31. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
32. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
Horn H; Staiger AM; Ott G
Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
[TBL] [Abstract][Full Text] [Related]
33. Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.
Kalinkova L; Sevcikova A; Stevurkova V; Fridrichova I; Ciernikova S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614080
[TBL] [Abstract][Full Text] [Related]
34. Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors.
Liu Z; Gao Y; Li X
Expert Rev Anticancer Ther; 2019 Feb; 19(2):139-149. PubMed ID: 30470148
[No Abstract] [Full Text] [Related]
35. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
Markozashvili D; Ribrag V; Vassetzky YS
Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
[TBL] [Abstract][Full Text] [Related]
36. At the tipping point for epigenetic therapies in cancer.
Jones PA
J Clin Invest; 2014 Jan; 124(1):14-6. PubMed ID: 24382384
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional and epigenetic networks in haematological malignancy.
Cheung N; So CW
FEBS Lett; 2011 Jul; 585(13):2100-11. PubMed ID: 21477587
[TBL] [Abstract][Full Text] [Related]
38. BCL6 as a therapeutic target for lymphoma.
Leeman-Neill RJ; Bhagat G
Expert Opin Ther Targets; 2018 Feb; 22(2):143-152. PubMed ID: 29262721
[TBL] [Abstract][Full Text] [Related]
39. Investigational drugs for the treatment of cervical cancer.
Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
[TBL] [Abstract][Full Text] [Related]
40. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
Guazzelli A; Bakker E; Tian K; Demonacos C; Krstic-Demonacos M; Mutti L
Expert Opin Investig Drugs; 2017 Aug; 26(8):933-944. PubMed ID: 28679291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
